Effect of bone strontium on BMD measurements.
Strontium ranelate is a new treatment for osteoporosis that is of interest for, among other reasons, its unusual effect on measurements of bone mineral density (BMD). When some of the calcium in bone is replaced by strontium, X-ray absorptiometry measurements of BMD are overestimated because strontium attenuates X-rays more strongly than calcium. In this study, we report the first theoretical estimation of this effect for measurements made using axial (spine and hip) dual-energy X-ray absorptiometry (DXA), peripheral DXA (pDXA), and single-energy quantitative computed tomography (SEQCT). Tables of X-ray attenuation coefficients were used to calculate values of the strontium ratio defined as the ratio of the percentage overestimation of BMD to the molar percentage of strontium (%Sr/[Ca+Sr]) in bone. For DXA measurements, the theoretical value of the strontium ratio increased slightly with increasing effective photon energy of the X-ray beam with figures of 9.0 for Osteometer DTX200 and G4 pDXA devices (Osteometer Meditech Inc., Hawthorne, CA), 10.0 for GE-Lunar DPX and Prodigy DXA systems (GE-Lunar, Madison, WI), 10.4 for Hologic QDR1000 and QDR2000, and 10.8 for Hologic QDR4500 and Discovery (Hologic Inc., Bedford, MA). Results for SEQCT also varied with the effective photon energy with strontium ratios of 6.2 at 60 keV and 4.4 at 80 keV. The results of the theoretical study are in good agreement with the experimental value of 10 reported by Pors Nielsen and colleagues for a variety of different axial DXA systems. A reliable figure for the strontium ratio is important for adjusting BMD measurements in strontium ranelate treated patients for the effect of bone strontium content. This latter correction will be required for the interpretation of future DXA scans in patients who have discontinued strontium ranelate treatment.
Blake
Glen M
GM
King's College London School of Medicine, London, UK. glen.blake@kcl.ac.uk
Fogelman
Ignac
I
D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000737:chemistry* / Q000187:drug effects; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*
D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate